Spurred by George Schett and Andreas Mackensen’s remarkable CAR-T results in SLE, the immunotherapy revolution for autoimmune diseases is the next “million-dollar question”.

Shifting from broad symptomatic treatment to wiping out the wrongdoings for sustained disease modification, cell therapies, cell engagers, and cell-depleting antibodies are promising a whole new level of therapeutic efficacy.

Beacon Targeted Therapies Trial Database cites 62 clinical trials in immune-mediated diseases with cell therapy alone, of which 42 are recruiting patients in 2024.

Combined with immune tolerization to rebuild a less aberrant immune system through engineered Tregs and antigen-specific immune tolerance strategies; immune reset and subsequent reconstitution is gathering industry momentum, to change treatment paradigms dramatically.

But despite this industry “gold rush” the average biotech-pharma collaboration takes 8 months, elongated from not finding the right individuals sooner.

The Autoimmunity Pharma & Biotech Partnering Summit is the only event of its kind, laying enabled partnering on top of hyper-relevant scientific discussion specifically for immune reset and reconstitution therapies.

Pharma will develop scientific growth strategies and evaluate modalities side-by-side, and biotech accesses the right gatekeepers for decision makers, or decision-makers themselves specific to immunology deal-making.